2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130259
    LC3-mHTT-IN-AN2 7758-73-8
    LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons.
    LC3-mHTT-IN-AN2
  • HY-16743B
    Ibiglustat succinate 1629063-80-4 99.92%
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat succinate
  • HY-B0411A
    Domperidone monomaleate 83898-65-1 99.76%
    Domperidone (R33812) monomaleate is an orally active and selective dopamine-2 receptor antagonist. Domperidone monomaleate acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine.
    Domperidone monomaleate
  • HY-106408A
    Nelonemdaz potassium 916214-57-8 99.86%
    Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death.
    Nelonemdaz potassium
  • HY-N0473S4
    L-Tyrosine-13C 110622-46-3 98.6%
    L-Tyrosine-13C is the 13C-labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
    L-Tyrosine-13C
  • HY-13999
    NSI-189 1270138-40-3 99.57%
    NSI-189 is an orally active chemical entity with enhanced neurogenic activity. NSI-189 up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. NSI-189 exhibits anti-depressant effect. NSI-189 enhances synaptic plasticity and reduces cognitive dysfunction. NSI-189 holds potential for psychiatric disorder research.
    NSI-189
  • HY-B1332
    Ipratropium bromide hydrate 66985-17-9 99.90%
    Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma.
    Ipratropium bromide hydrate
  • HY-110037
    MRS-3777 hemioxalate 1186195-57-2
    MRS-3777 hemioxalate is a selective adenosine A3 receptor antagonist.
    MRS-3777 hemioxalate
  • HY-112279
    GNE-131 1629063-81-5 98.15%
    GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.
    GNE-131
  • HY-120124
    Samelisant 1394808-20-8 98.65%
    Samelisant (SUVN-G3031) is a potent and selective histamine H3 receptor (H3R) inverse agonist with good brain penetration and oral bioavailability. Samelisant has a similar binding affinity towards human (hH3R; Ki=8.7 nM) and rat (rH3R;Ki=9.8 nM) H3R indicating no inter-species differences. Samelisant can be used for the research of sleep-related disorders.
    Samelisant
  • HY-123820
    LY3020371 hydrochloride 1377615-44-5 99.18%
    LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM. LY3020371 hydrochloride exerts an antidepressant-like signature in vivo.
    LY3020371 hydrochloride
  • HY-130630
    mGluR2 modulator 1 2671063-84-4 ≥98.0%
    mGluR2 modulator 1 (compound 95) is a potent and BBB-penetrated mGluR2 (metabotropic glutamate receptor-2) positive allosteric modulator, with an EC50 of 0.03 μM. mGluR2 modulator 1 can be used for psychosis research.
    mGluR2 modulator 1
  • HY-142647
    EB-42486 2390475-81-5 99.62%
    EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM).
    EB-42486
  • HY-144267
    Glucosylceramide synthase-IN-2 2597958-02-4 98.62%
    Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-2
  • HY-152107
    LRRK2-IN-7 2307277-93-4 98.04%
    LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
    LRRK2-IN-7
  • HY-B0166G
    L-Ascorbic acid (GMP) 50-81-7 98%
    L-Ascorbic acid (L-Ascorbate) (GMP) is L-Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Cav 3.2 channels.
    L-Ascorbic acid (GMP)
  • HY-P99216
    Ponezumab 1178862-65-1 99.39%
    Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.
    Ponezumab
  • HY-132392S
    L-DOPA-2,5,6-d3 53587-29-4 98.80%
    L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain.
    L-DOPA-2,5,6-d3
  • HY-19946
    Eptapirone 179756-58-2 99.91%
    Eptapirone (F11440) is a potent and selective 5-HT1A receptor agonist (pKi= 8.33) with marked anxiolytic and antidepressant potential.
    Eptapirone
  • HY-A0057S
    Gabapentin-d4 1185039-20-6 ≥99.0%
    Gabapentin-d4 is the deuterium labeled Gabapentin. Gabapentin (Neurontin) is a pharmaceutical agent, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.
    Gabapentin-d4
Cat. No. Product Name / Synonyms Application Reactivity